IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12084516 B1

PDFFull Text
Date of Patent:
Sep. 10, 2024

Filed:

May. 17, 2022

Anti-c5 antibody combinations and uses thereof

Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventor:

Kishor Devalaraja-Narashimha, Yorktown Heights, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:

Fox Rothschild, LLP

Thomas Triolo

Primary Examiner:

Christine J Saoud

Assistant Examiner:

Jon M Lockard

Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61P 3/06 (2006.01); A61P 7/04 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 43/00 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C07K 16/34 (2006.01); C07K 16/40 (2006.01); C07K 16/44 (2006.01); A61K 31/573 (2006.01); A61K 31/727 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/44 (2013.01); A61K 39/3955 (2013.01); A61P 3/06 (2018.01); A61P 7/04 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 43/00 (2018.01); C07K 14/472 (2013.01); C07K 16/18 (2013.01); C07K 16/34 (2013.01); C07K 16/40 (2013.01); A61K 31/573 (2013.01); A61K 31/727 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to combinations of anti-C5 antibodies and antigen-binding fragments which have been determined to exhibit superior activity relative to that of a single anti-C5 antibody or fragment. The combinations include anti-C5 antibodies and antigen-binding fragments which do not compete with one another from C5 binding. Bispecific antibodies comprising antigen-binding domains which do not compete and/or bind the same epitope on C5 are also provided. Compositions and therapeutic methods relating to such anti-C5 combinations and bispecific antibodies are provided herein.

Find Patent Forward Citations

Loading…